A woman presenting with amenorrhea and galactorrhea is diagnosed with a pituitary adenoma and elevated prolactin levels. What is the most likely cause of her amenorrhea?

Explanation

## Correct Answer: D. Low GnRH Hyperprolactinemia from a prolactin-secreting pituitary adenoma causes amenorrhea through **suppression of GnRH pulsatile secretion** from the hypothalamus, not direct inhibition of the pituitary gonadotropes. The mechanism is dopamine-dependent: prolactin inhibits dopamine release from the hypothalamus, and dopamine is the primary physiological inhibitor of prolactin. When prolactin levels are elevated, there is a compensatory reduction in hypothalamic dopamine, which disrupts the normal pulsatile GnRH secretion pattern. GnRH must be secreted in a specific pulsatile manner (every 60–90 minutes) to stimulate FSH and LH release; continuous or absent GnRH signaling fails to trigger gonadotropin secretion. Thus, the **primary defect is low/absent GnRH pulsatility**, not high or low absolute gonadotropin levels. This is why dopamine agonists (bromocriptine, cabergoline) are the first-line treatment in India—they restore dopamine tone, normalize prolactin, and restore GnRH pulsatility, leading to resumption of menses. The amenorrhea resolves when GnRH pulsatile secretion is restored, confirming that the hypothalamic-level defect is the root cause. ## Why the other options are wrong **A. Inhibition of GnRH by prolactin** — This is mechanistically incorrect. Prolactin does not directly inhibit GnRH neurons; rather, it suppresses dopamine release, which indirectly reduces GnRH pulsatility. Prolactin acts on the hypothalamus via dopamine suppression, not via direct GnRH neuron inhibition. This is a common NBE trap—students confuse the indirect dopamine-mediated effect with direct prolactin action on GnRH. **B. High FSH** — FSH levels are typically **low or normal** in hyperprolactinemia-induced amenorrhea because GnRH pulsatility is reduced, leading to inadequate FSH stimulation. High FSH would suggest primary ovarian failure (hypergonadotropic hypogonadism), not central hypogonadism. This option misrepresents the gonadotropin pattern in prolactinoma. **C. High pulsed LH** — LH levels are low or absent in hyperprolactinemia because reduced GnRH pulsatility fails to stimulate LH secretion adequately. High pulsed LH would occur in PCOS or primary ovarian disease, not in prolactinoma. This option confuses the gonadotropin axis dysfunction pattern. ## High-Yield Facts - **Hyperprolactinemia suppresses GnRH pulsatility** via dopamine inhibition, not direct prolactin action on GnRH neurons. - **Dopamine agonists (bromocriptine, cabergoline)** are first-line DOC for prolactinoma in India; they restore dopamine tone and GnRH pulsatility. - **GnRH must be pulsatile** (every 60–90 min) to stimulate FSH/LH; continuous or absent GnRH causes hypogonadism. - **Amenorrhea in prolactinoma is hypogonadotropic** (low FSH, low LH), not hypergonadotropic. - **Galactorrhea + amenorrhea + elevated prolactin** is pathognomonic for prolactin-secreting adenoma; MRI confirms diagnosis. ## Mnemonics **DOPAMINE RULE in Prolactinoma** **D**opamine ↓ → **P**rolactin ↑ → **G**nRH pulsatility ↓ → **A**menorrhea. Restore dopamine = restore GnRH = restore menses. **Hypogonadotropic vs Hypergonadotropic** **Prolactinoma** = low GnRH → low FSH/LH (hypogonadotropic). **Ovarian failure** = high FSH/LH (hypergonadotropic). Prolactinoma = central defect; ovarian failure = peripheral defect. ## NBE Trap NBE pairs "prolactin inhibits GnRH" with prolactinoma to trap students who confuse indirect dopamine-mediated suppression with direct prolactin action. The correct mechanism is dopamine-dependent GnRH suppression, not direct prolactin-GnRH interaction. ## Clinical Pearl In Indian clinical practice, any woman presenting with amenorrhea + galactorrhea should have serum prolactin measured immediately. If elevated, MRI pituitary confirms adenoma, and dopamine agonists (bromocriptine 2.5–5 mg daily or cabergoline 0.25–0.5 mg twice weekly) are started. Menses typically resume within 2–3 months as GnRH pulsatility is restored—this clinical response confirms the hypothalamic mechanism. _Reference: KD Tripathi Pharmacology Ch. 32 (Hypothalamic-Pituitary Hormones); Harrison Ch. 375 (Pituitary Disorders)_